

# Amanda Haymond

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6966456/amanda-haymond-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

16  
papers

177  
citations

7  
h-index

13  
g-index

16  
ext. papers

226  
ext. citations

4.6  
avg, IF

2.58  
L-index

#	Paper	IF	Citations
16	Protein biomarkers for subtyping breast cancer and implications for future research. <i>Expert Review of Proteomics</i> , <b>2018</b> , 15, 131-152	4.2	35
15	Synthesis and bioactivity of $\beta$ -substituted fosmidomycin analogues targeting 1-deoxy-D-xylulose-5-phosphate reductoisomerase. <i>Journal of Medicinal Chemistry</i> , <b>2015</b> , 58, 2988-3001	8.3	26
14	Design of Potential Bisubstrate Inhibitors against (Mtb) 1-Deoxy-D-Xylulose 5-Phosphate Reductoisomerase (Dxr)-Evidence of a Novel Binding Mode. <i>MedChemComm</i> , <b>2013</b> , 4, 1099-1104	5	20
13	The effect of chain length and unsaturation on Mtb Dxr inhibition and antitubercular killing activity of FR900098 analogs. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2014</b> , 24, 649-53	2.9	20
12	Structure-Activity Relationships of the MEPicides: N-Acyl and O-Linked Analogs of FR900098 as Inhibitors of Dxr from Mycobacterium tuberculosis and Yersinia pestis. <i>ACS Infectious Diseases</i> , <b>2016</b> , 2, 923-935	5.5	20
11	MEPicides: $\beta$ -Unsaturated Fosmidomycin Analogues as DXR Inhibitors against Malaria. <i>Journal of Medicinal Chemistry</i> , <b>2018</b> , 61, 8847-8858	8.3	16
10	Kinetic characterization and allosteric inhibition of the Yersinia pestis 1-deoxy-D-xylulose 5-phosphate reductoisomerase (MEP synthase). <i>PLoS ONE</i> , <b>2014</b> , 9, e106243	3.7	14
9	Protein painting, an optimized MS-based technique, reveals functionally relevant interfaces of the PD-1/PD-L1 complex and the YAP2/ZO-1 complex. <i>Journal of Biological Chemistry</i> , <b>2019</b> , 294, 11180-11198	5.4	6
8	Seropositivity of COVID-19 among asymptomatic healthcare workers: A multi-site prospective cohort study from Northern Virginia, United States. <i>The Lancet Regional Health Americas</i> , <b>2021</b> , 2, 100030		4
7	Proteomics for cancer drug design. <i>Expert Review of Proteomics</i> , <b>2019</b> , 16, 647-664	4.2	3
6	VOC fingerprints: metabolomic signatures of biothreat agents with and without antibiotic resistance. <i>Scientific Reports</i> , <b>2020</b> , 10, 11746	4.9	3
5	Next Generation Techniques for Determination of Protein-Protein Interactions: Beyond the Crystal Structure. <i>Current Pathobiology Reports</i> , <b>2019</b> , 7, 61-71	2	2
4	Clinical Utility of a Highly Sensitive Lateral Flow Immunoassay as determined by Titer Analysis for the Detection of anti-SARS-CoV-2 Antibodies at the Point-of-Care <b>2020</b> ,		2
3	Durability of Viral Neutralization in Asymptomatic Coronavirus Disease 2019 for at Least 60 Days. <i>Journal of Infectious Diseases</i> , <b>2021</b> , 223, 1677-1680	7	2
2	Serological Testing for COVID-19 Disease: Moving the Field of Serological Surveillance Forward. <i>Journal of Applied Laboratory Medicine</i> , <b>2021</b> , 6, 584-587	2	2
1	A high-throughput screening campaign to identify inhibitors of DXP reductoisomerase (IspC) and MEP cytidyltransferase (IspD). <i>Analytical Biochemistry</i> , <b>2018</b> , 542, 63-75	3.1	2